TY - JOUR
T1 - Type 2 diabetes and cardiometabolic risk may be associated with increase in DNA methylation of FKBP5
AU - Ortiz, Robin
AU - Joseph, Joshua J.
AU - Lee, Richard
AU - Wand, Gary S.
AU - Golden, Sherita Hill
N1 - Funding Information:
The project described was supported by Award Number Grant UL1TR001070 from the National Center For Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Advancing Translational Sciences or the National Institutes of Health. This study was supported by the National Institute of Diabetes, Digestive, and Kidney Diseases (R03 DK088997 awarded to SHG) and the National Institute of Alcohol Abuse and Alcoholism (U01 AA020890 awarded to GSW).
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/6/19
Y1 - 2018/6/19
N2 - Background: Subclinical hypercortisolism and hypothalamic-pituitary-adrenal (HPA) axis dysfunction are associated with type 2 diabetes (T2DM), cardiovascular disease, and metabolic dysfunction. Intronic methylation of FKBP5 has been implicated as a potential indicator of chronic cortisol exposure. Our overall objective in this study was to determine the association of chronic cortisol exposure, measured via percent methylation of FKBP5 at intron 2, with percent glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-cholesterol), waist circumference (WC), and body mass index (BMI), in a clinic-based sample of 43 individuals with T2DM. Results: Greater percent methylation of the FKBP5 intron 2 at one CpG-dinucleotide region was significantly associated with higher HbA1c (β = 0.535, p = 0.003) and LDL cholesterol (β = 0.344, p = 0.037) and a second CpG-dinucleotide region was significantly associated with higher BMI and WC (β = 0.516, p = 0.001; β = 0.403, p = 0.006, respectively). Conclusions:FKBP5 methylation may be a marker of higher metabolic risk in T2DM, possibly secondary to higher exposure to cortisol. Further work should aim to assess the longitudinal association of FKBP5 with cardiovascular disease and glycemic outcomes in T2DM as a first step in understanding potential preventive and treatment-related interventions targeting the HPA axis.
AB - Background: Subclinical hypercortisolism and hypothalamic-pituitary-adrenal (HPA) axis dysfunction are associated with type 2 diabetes (T2DM), cardiovascular disease, and metabolic dysfunction. Intronic methylation of FKBP5 has been implicated as a potential indicator of chronic cortisol exposure. Our overall objective in this study was to determine the association of chronic cortisol exposure, measured via percent methylation of FKBP5 at intron 2, with percent glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-cholesterol), waist circumference (WC), and body mass index (BMI), in a clinic-based sample of 43 individuals with T2DM. Results: Greater percent methylation of the FKBP5 intron 2 at one CpG-dinucleotide region was significantly associated with higher HbA1c (β = 0.535, p = 0.003) and LDL cholesterol (β = 0.344, p = 0.037) and a second CpG-dinucleotide region was significantly associated with higher BMI and WC (β = 0.516, p = 0.001; β = 0.403, p = 0.006, respectively). Conclusions:FKBP5 methylation may be a marker of higher metabolic risk in T2DM, possibly secondary to higher exposure to cortisol. Further work should aim to assess the longitudinal association of FKBP5 with cardiovascular disease and glycemic outcomes in T2DM as a first step in understanding potential preventive and treatment-related interventions targeting the HPA axis.
KW - Body mass index (BMI)
KW - Cardiovascular disease
KW - Cortisol
KW - Diabetes
KW - Epigenetics
KW - FKBP5
KW - Hemoglobin A1c
KW - Methylation
KW - Obesity
KW - Waist circumference
UR - http://www.scopus.com/inward/record.url?scp=85048826848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048826848&partnerID=8YFLogxK
U2 - 10.1186/s13148-018-0513-0
DO - 10.1186/s13148-018-0513-0
M3 - Article
C2 - 29951131
AN - SCOPUS:85048826848
SN - 1868-7075
VL - 10
JO - Clinical Epigenetics
JF - Clinical Epigenetics
IS - 1
M1 - 82
ER -